Tuesday, September 14, 2021 Daily Archives

Transient Technologies to Deliver Consistently High AAV Titers

by

This webcast features: Dr. Jason King, Business Development Manager, OXGENE Adenoassociated virus (AAV) is often the vector of choice for gene therapies; in fact, AAV represents around 37% of the current advanced therapies market. And when it comes to manufacturing AAV for in vivo gene therapies, developers must pursue triplicate goals of quality, quantity, and speed. Here, Dr. Jason King presents the quality, titer, and regulatory advantages of OXGENE’s AAV plasmid system. He discusses the key quality considerations of WuXi Advanced…

September 14, 2021

Minimize Risks and Enhance Speed and Flexibility with Sterile Fill/Finish Support for Clinical Supplies

by

Industry changes, such as shorter timelines and increased product complexity, can often introduce additional risks to the sterile fill/finish process, resulting in production delays, additional costs, and safety concerns. Additionally, the advent of personalized medicines brings challenges to manufacturing and supply chain structure, emphasizing the need for speed and flexibility. Join Eurofins BioPharma Product Testing and Vanrx (now part of Cytiva), for an in-depth discussion covering ways to eliminate human error and other associated risks when producing small batches of…

September 14, 2021

Managing Frozen Transport Logistics in the Biopharmaceutical Cold Chain

by

The enormous task of establishing a reliable infrastructure to supply COVID-19 vaccines across the globe has thrust cold chain shipping and its associated challenges into the spotlight. Valuable biologics, such as vaccines and recombinant therapeutic proteins, are often kept in a frozen state during storage and shipping. This requires robust solutions to ensure temperatures do not fluctuate and product integrity is preserved. As biopharmaceutical manufacturing grows increasingly global, the production and transport networks required to keep operations running smoothly become…

September 14, 2021

Flash drive: French CDMO to scale up viral vector production

by

Flash Therapeutics has secured a three-year funding deal to help further develop its LentiFlash viral vector tech and to double its manufacturing capacity. The Toulouse, France-based contract development and manufacturing organization (CDMO) has developed its own lentiviral platform, LentiFlash, for use as a delivery vector in vaccinations, regenerative medicine, and gene-editing applications. “LentiFlash technology leads to a transient expression mediated by RNA delivery as lentiviral-based therapies leads to stable expression mediated by DNA delivery,†a spokesman from the firm told…

September 14, 2021

Affinia strikes strategic AAV manufacturing deal with Lonza

by

Affinia has signed a multi-year agreement with CDMO Lonza to make gene therapy candidates targeting cancer and neurological disorders. Swiss contract development manufacturing organization (CDMO) Lonza will provide manufacturing services for Affinia Therapeutics for two of its gene therapy candidates targeting metachromatic leukodystrophy (MLD), a rare neurodegenerative disease, and brain metastases secondary to human epidermal growth factor receptor 2 positive (HER2+) breast cancer. Both candidates are based on the firm’s lead adeno-associated virus (AAV) vector, Anc80L65. Anc80L65-ARSA aims to treat…

September 14, 2021

Ins & Outs: Genezen new CEO to lead transition into full service CDMO

by

Ray Kaczmarek, the new CEO of Genezen, figuratively sat down with BioProcess Insider to discuss his strategy and aims for the firm. Sit back, relax, and enjoy this week’s Ins and outs. Kaczmarek has spent the past 20 years in pharmaceutical and biotechnology manufacturing, as well as supply chain operations, serving in senior roles at Trilink Biotechnologies, Nitto Avecia Pharma Services, and Pacira Biosciences. His latest career move takes him to contract development manufacturing organization (CDMO) Genezen, where he serves as…

September 14, 2021